These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
475 related articles for article (PubMed ID: 9422471)
41. Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial. Fennelly D; Wasserheit C; Schneider J; Hakes T; Reich L; Curtin J; Yao TJ; Markman M; Norton L; Crown J Cancer Res; 1994 Dec; 54(23):6137-42. PubMed ID: 7525055 [TBL] [Abstract][Full Text] [Related]
42. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. Gianni AM; Siena S; Bregni M; Di Nicola M; Orefice S; Cusumano F; Salvadori B; Luini A; Greco M; Zucali R; Rilke F; Zambetti M; Valagussa P; Bonadonna G J Clin Oncol; 1997 Jun; 15(6):2312-21. PubMed ID: 9196145 [TBL] [Abstract][Full Text] [Related]
43. High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer. Cagnoni PJ; Nieto Y; Shpall EJ; Bearman SI; Barón AE; Ross M; Matthes S; Dunbar SE; Jones RB J Clin Oncol; 1998 May; 16(5):1661-8. PubMed ID: 9586876 [TBL] [Abstract][Full Text] [Related]
44. High dose chemotherapy and peripheral blood stem cell transplantation for high risk primary breast cancer: a single center experience in Thailand. Ungkanont A; Jootar S; Ratanatharathorn V; Chiernsilp A Asian Pac J Allergy Immunol; 2000 Dec; 18(4):215-20. PubMed ID: 11316042 [TBL] [Abstract][Full Text] [Related]
45. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma. Haas R; Moos M; Möhle R; Döhner H; Witt B; Goldschmidt H; Murea S; Flentje M; Wannenmacher M; Hunstein W Bone Marrow Transplant; 1996 Feb; 17(2):149-55. PubMed ID: 8640159 [TBL] [Abstract][Full Text] [Related]
46. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Elias AD; Ayash L; Anderson KC; Hunt M; Wheeler C; Schwartz G; Tepler I; Mazanet R; Lynch C; Pap S Blood; 1992 Jun; 79(11):3036-44. PubMed ID: 1350229 [TBL] [Abstract][Full Text] [Related]
47. Reinfusion of autologous lymphocytes with granulocyte-macrophage colony-stimulating factor induces rapid recovery of CD4+ and CD8+ T cells after high-dose chemotherapy for metastatic breast cancer. de Gast GC; Vyth-Dreese FA; Nooijen W; van den Bogaard CJ; Sein J; Holtkamp MM; Linthorst GA; Baars JW; Schornagel JH; Rodenhuis S J Clin Oncol; 2002 Jan; 20(1):58-64. PubMed ID: 11773154 [TBL] [Abstract][Full Text] [Related]
48. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study. Ayash LJ; Elias A; Wheeler C; Reich E; Schwartz G; Mazanet R; Tepler I; Warren D; Lynch C; Gonin R J Clin Oncol; 1994 Jan; 12(1):37-44. PubMed ID: 7505807 [TBL] [Abstract][Full Text] [Related]
49. Mobilization of peripheral blood progenitor cells (PBPC) in patients undergoing chemotherapy followed by autologous peripheral blood stem cell transplant (SCT) for high risk breast cancer (HRBC). Benet I; Prosper BF; Marugan I; Lluch A; Arbona C; Castillo I; Solano C; Garcia-Conde J Bone Marrow Transplant; 1999 Jun; 23(11):1101-7. PubMed ID: 10382948 [TBL] [Abstract][Full Text] [Related]
50. Phase II study of high-dose cyclophosphamide, etoposide, and carboplatin (CEC) followed by autologous hematopoietic stem cell rescue in women with metastatic or high-risk non-metastatic breast cancer: multivariate analysis of factors affecting survival and engraftment. Klumpp TR; Goldberg SL; Magdalinski AJ; Mangan KF Bone Marrow Transplant; 1997 Aug; 20(4):273-81. PubMed ID: 9285541 [TBL] [Abstract][Full Text] [Related]
51. Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost. Lee SM; Radford JA; Dobson L; Huq T; Ryder WD; Pettengell R; Morgenstern GR; Scarffe JH; Crowther D Br J Cancer; 1998 Apr; 77(8):1294-9. PubMed ID: 9579836 [TBL] [Abstract][Full Text] [Related]
52. Mobilization of peripheral blood progenitor cells (PBPC) through a combination of chemotherapy and G-CSF in breast cancer patients and a possibility of unprocessed whole blood collection. Vanásek J; Filip S; Medková V; Bláha M; Mericka P; Volenec K Bone Marrow Transplant; 1998 Jan; 21(2):123-6. PubMed ID: 9489627 [TBL] [Abstract][Full Text] [Related]
53. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. Crump M; Gluck S; Tu D; Stewart D; Levine M; Kirkbride P; Dancey J; O'Reilly S; Shore T; Couban S; Girouard C; Marlin S; Shepherd L; Pritchard KI J Clin Oncol; 2008 Jan; 26(1):37-43. PubMed ID: 18025439 [TBL] [Abstract][Full Text] [Related]
54. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Schmitz N; Linch DC; Dreger P; Goldstone AH; Boogaerts MA; Ferrant A; Demuynck HM; Link H; Zander A; Barge A Lancet; 1996 Feb; 347(8998):353-7. PubMed ID: 8598700 [TBL] [Abstract][Full Text] [Related]
55. Efficacy and toxicity of sequential high-dose therapy with peripheral blood stem cell support in patients with high-risk breast cancer. Hohaus S; Wallwiener D; Martin S; Voso MT; Huober J; Fersis N; Bastert G; Haas R Semin Oncol; 1998 Apr; 25(2 Suppl 4):7-11; discussion 45-8. PubMed ID: 9578056 [TBL] [Abstract][Full Text] [Related]
56. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer. Jones SE; Schottstaedt MW; Duncan LA; Kirby RL; Good RH; Mennel RG; George TK; Snyder DA; Watkins DL; Denham CA; Hoyes FA; Rubin AS J Clin Oncol; 1996 Nov; 14(11):2976-83. PubMed ID: 8918495 [TBL] [Abstract][Full Text] [Related]
57. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. Weaver CH; Schulman KA; Buckner CD Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117 [TBL] [Abstract][Full Text] [Related]
58. Intensified chemotherapy supported by DMSO-free peripheral blood progenitor cells in breast cancer patients. Del Mastro L; Venturini M; Viscoli C; Bergaglio M; Signorini A; Bighin C; Bertelli G; Semino C; Pietra G; Bertoglio S; Sertoli MR; Lambiase A; Rosso R; Melioli G Ann Oncol; 2001 Apr; 12(4):505-8. PubMed ID: 11398884 [TBL] [Abstract][Full Text] [Related]
59. [Combination of high-dose chemotherapy with autologous hematopoietic stem cell transplantation for recurrent and high-risk breast cancer: a pilot study]. Shi Y; Pan F; Han X Zhonghua Yi Xue Za Zhi; 1999 Dec; 79(12):890-3. PubMed ID: 11715500 [TBL] [Abstract][Full Text] [Related]
60. Double-cycle high-dose chemotherapy with peripheral blood stem cells and hematopoietic growth factor support in patients with advanced solid tumor. A pilot study by the Hong Kong Biotherapy Group. Yeung AW; Pang YK; Tsang YC; Wong SW Cancer; 1994 Apr; 73(7):1960-70. PubMed ID: 7511042 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]